Lana is a biopharmaceutical industry veteran with over 20 years of pharmaceutical development experience that spans the full life cycle of therapeutic product development. Lana currently acts as a Venture Partner at The Centre for Drug Research and Development (CDRD) in Vancouver, BC, where she is focused on identifying compelling areas of strategic commercial opportunity in the therapeutic space, and driving the creation and acceleration of new companies to develop those opportunities into innovative therapies. Prior to that, she worked for many years at QLT Inc. in Vancouver (now Novelion Therapeutics Inc.) where she served as Senior Vice President, Intellectual Property and Technology Development and Chief Patent Officer, with leadership and oversight responsibilities for all R&D aspects of Novelion’s late stage ophthalmology orphan assets. Lana has extensive experience in negotiating and executing licensing, co-development, merger, acquisition, divestiture, and joint development transactions for various technologies in the biopharma and medical device spaces. Lana worked for several years as a registered patent agent (Canada and the US) in the Toronto offices of Blake, Cassels & Graydon LLP, and Ogilvy Renault LLP (now Norton Rose Fulbright), and has also served as an in-house patent agent at F. Hoffmann-La Roche in Basel, Switzerland, where her practice focused on the strategic development and protection of IP portfolios in the fields of pharmaceutical and biological products. Lana received her AB in Chemistry with honors from Harvard University and her Ph.D. in organic chemistry from McGill University, where she also conducted post-Doctoral work in the field of biological organic chemistry.